Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data



Rating:

Share or cite this content

Citations should be made in the following way:
K. Rothnie (London, United Kingdom), A. Czira (London, United Kingdom), C. Compton (London, United Kingdom), V. Banks (Bollington, United Kingdom), R. Wood (Bollington, United Kingdom), T. Tritton (Bollington, United Kingdom), J. Thomas (Bollington, United Kingdom), O. Massey (Bollington, United Kingdom), S. Blackburn (Bollington, United Kingdom), R. Wild (Bollington, United Kingdom), A. Ismaila (Upper Providence, United States of America). Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?. 2947

Member's Comments

No comment yet.

Related content which might interest you: Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Characteristics of COPD patients prescribed ICS managed in general practice vs. secondary care Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021 Characteristics of patients receiving inhaled treatment in primary care Source: Annual Congress 2009 - Respiratory physiology Year: 2009 Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021 Year: 2022 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017 Characteristics of COPD patients treated with inhaled corticosteroid in primary care Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Characteristics of new users of single and multiple-inhaler triple therapy for COPD in primary care in England Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Assessment and therapy for COPD patients in real-life primary care Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018 Comparison of dual vs triple therapies in patients hospitalized for COPD in France: a claims data study Source: International Congress 2018 – COPD management Year: 2018 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 SABA and ICS use among mild asthma patients in UK primary care Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021 Symptomatic burden of COPD for patients receiving dual or triple therapy Source: International Congress 2017 – Management of COPD Year: 2017 De-implementing inappropriate inhaled steroids use in Dutch COPD patients in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019